Company Update (NASDAQ:GALE): Galena Biopharma Inc to Present GALE-401 Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, announced that data from the Company’s Phase 2 clinical trial of GALE-401, or Anagrelide Controlled Release, will be presented at the upcoming European Hematology Association 20th Congress in Vienna, Austria. Details of the poster presentation are as follows:
||Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis
||Myeloproliferative neoplasms – Clinical 2
||Saturday, June 13, 2015
||5:15 p.m. to 6:45 p.m. local time
||Poster area (Hall C) (Original Source)
Shares of Galena Biopharma closed yesterday at $1.33. GALE has a 1-year high of $3.58 and a 1-year low of $1.28. The stock’s 50-day moving average is $1.38 and its 200-day moving average is $1.61.
On the ratings front, Galena has been the subject of a number of recent research reports. In a report issued on April 14, Roth Capital analyst Joseph Pantginis maintained a Buy rating on GALE, with a price target of $8, which represents a potential upside of 501.5% from where the stock is currently trading. Separately, on March 30, Maxim Group’s Jason Kolbert maintained a Buy rating on the stock and has a price target of $7.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Jason Kolbert have a total average return of 7.0% and 2.6% respectively. Pantginis has a success rate of 50.6% and is ranked #382 out of 3607 analysts, while Kolbert has a success rate of 41.7% and is ranked #1234.
Overall, one research analyst has rated the stock with a Sell rating, 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $1.33 which is 245.9% above where the stock closed yesterday.
Galena Biopharma Inc, is abiopharmaceutical company focused on developing and commercializing targeted oncology therapeutics that address medical needs across the full spectrum of cancer care.